Researchers at the University of Oxford have officially launched the first human clinical trial for a vaccine candidate specifically targeting the Bundibugyo ebolavirus. The experimental vaccine, known as ChAdOx BDBV, is being evaluated in a Phase I study involving 50 healthy adult volunteers aged 18–55 years.
Oxford Launches First Human Trial for Bundibugyo Ebola Vaccine
Led by the Oxford Vaccine Group and the Pandemic Sciences Institute, the trial aims to assess the safety of the vaccine and its ability to stimulate an immune response against the Bundibugyo species. While the current outbreak in the Democratic Republic of the Congo (DRC) has claimed more than 1,000 lives and resulted in over 2,500 confirmed cases, this study represents the first clinical evaluation of a vaccine designed to combat this specific strain.
Utilizing Proven Vaccine Technology
The ChAdOx BDBV vaccine candidate utilizes the same chimpanzee adenovirus vector platform employed in the development of the Oxford-AstraZeneca COVID-19 vaccine. According to the Oxford team, this established technology has allowed for the rapid progression of the vaccine into human testing, mirroring the adaptable approaches used during the COVID-19 pandemic to address emerging infectious threats.
Rather than carrying instructions for the SARS-CoV-2 spike protein, this vaccine carries genetic instructions for a protein specific to the Bundibugyo virus. Prof Katrina Pollock, chief investigator at the Oxford Vaccine Group, described the launch of the first-in-human study as a significant milestone in vaccine development, manufacturing, and clinical testing.
To ensure rapid availability, the Serum Institute in India has already manufactured approximately 620,000 doses of the vaccine. If the current trial confirms that the candidate is safe and triggers a strong immune response, these doses could be utilized in larger efficacy studies and, following regulatory approval, deployed for public health use.
Addressing the Limitations of Existing Vaccines
The urgency surrounding the development of a Bundibugyo-specific vaccine stems from the fact that existing licensed vaccines are strain-specific. The only currently licensed Ebola vaccine, Ervebo (rVSV-ZEBOV), is designed to protect against the Zaire ebolavirus. While highly effective against the Zaire strain, it is not licensed for use against the Bundibugyo ebolavirus and is not expected to provide sufficient protection against the species currently driving the outbreak in the DRC.
Although some studies published in the New England Journal of Medicine suggest that existing vaccines like Ervebo and the two-dose regimen from Johnson & Johnson may elicit some cross-reactive antibody responses, experts emphasize that these findings do not provide proof of protection.
Future Outlook and Global Preparedness
The Bundibugyo outbreak—currently the third-largest Ebola outbreak on record—has underscored a critical gap in global health preparedness. Because the Ebola virus family consists of several genetically distinct species, immunity generated against one does not necessarily translate to protection against others.
While the Oxford trial is the first to reach the human testing stage for this specific virus, there are several other candidates in development as part of an international effort to expand the portfolio of available medical countermeasures. Dr. Jean Kaseya, Director General of the Africa Centres for Disease Control and Prevention (Africa CDC), noted that while early-stage trials are not an immediate solution for communities currently facing the outbreak, they are a critical component of building the tools necessary for future disease response.
Following the initial study in the U.K., the Oxford team plans to initiate a second, smaller trial in Uganda, followed by a larger efficacy study in the DRC. As health officials continue to manage the ongoing crisis through contact tracing, infection prevention, and supportive care, the progression of these clinical trials remains a primary focus for long-term outbreak control.
Keep reading
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.